[go: up one dir, main page]

PE20060372A1 - Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol - Google Patents

Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol

Info

Publication number
PE20060372A1
PE20060372A1 PE2005000742A PE2005000742A PE20060372A1 PE 20060372 A1 PE20060372 A1 PE 20060372A1 PE 2005000742 A PE2005000742 A PE 2005000742A PE 2005000742 A PE2005000742 A PE 2005000742A PE 20060372 A1 PE20060372 A1 PE 20060372A1
Authority
PE
Peru
Prior art keywords
methylpropyl
ethyl
phenol hydrochloride
dimethylamino
crystalline form
Prior art date
Application number
PE2005000742A
Other languages
English (en)
Inventor
Andreas Fischer
Helmut Buschmann
Dagmar Lischke
Michael Grub
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060372(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20060372A1 publication Critical patent/PE20060372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA A DEL CLORHIDRATO DE (-)-(1R,2R)-3-(3-DIETILAMINO-1-ETIL-2-METILPROPIL)-FENOL, QUE SE CARACTERIZA PORQUE LA CELDA ELEMENTAL TIENE FORMA MONOCICLICA Y POR EXHIBIR AL MENOS LINEAS DE RAYOS X (VALORES 2-THETA), EN UN DIAGRAMA DE DIFRACCION EN POLVOS, CUANDO SE MIDE POR MEDIO DEL USO DE RADIACION Cu KALFA, A 15,1+-0,2; 16,0+-0,2; 18,9+-0,2;20,4+-0,2; 22,5+-0,2; 27+-0,2, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHA FORMA CRISTALINA ES MAS ESTABLE FRENTE A LAS CONDICIONES AMBIENTALES, UTILES EN EL TRATAMIENTO DE DOLOR
PE2005000742A 2004-06-28 2005-06-27 Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol PE20060372A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number Publication Date
PE20060372A1 true PE20060372A1 (es) 2006-05-08

Family

ID=34925507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000742A PE20060372A1 (es) 2004-06-28 2005-06-27 Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol

Country Status (27)

Country Link
US (16) US20070213405A1 (es)
EP (2) EP1612203B1 (es)
JP (1) JP4990764B2 (es)
KR (1) KR101096501B1 (es)
CN (1) CN1997621B (es)
AR (2) AR049949A1 (es)
AT (2) ATE368639T1 (es)
AU (1) AU2005256512B2 (es)
BR (2) BRPI0512792A (es)
CA (1) CA2572147C (es)
CY (2) CY1106929T1 (es)
DE (2) DE602004007905T2 (es)
DK (2) DK1612203T3 (es)
EC (1) ECSP17046065A (es)
ES (2) ES2291780T3 (es)
HR (1) HRP20110050T8 (es)
IL (1) IL180373A (es)
MX (1) MXPA06014741A (es)
NO (3) NO338605B1 (es)
NZ (1) NZ551605A (es)
PE (1) PE20060372A1 (es)
PL (2) PL1612203T3 (es)
PT (2) PT1612203E (es)
RU (1) RU2423345C2 (es)
SI (2) SI1612203T1 (es)
WO (1) WO2006000441A2 (es)
ZA (1) ZA200700774B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
PT2240431T (pt) * 2007-12-07 2017-05-03 Gruenenthal Gmbh Modificações cristalinas de (1r,2r)-3-(3-dimetilamino-1- etil-2-metil-propil)fenol
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
DK2273983T3 (en) 2008-05-09 2016-09-19 Gruenenthal Gmbh A process for the preparation of a powdery formulation intermediate and a fixed final dosage form using a sprøjtestørkningstrin
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
PL2997965T3 (pl) 2009-07-22 2019-06-28 Grünenthal GmbH Odporna na manipulacje postać dawkowania opioidów wrażliwych na utlenianie
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
WO2011138037A2 (de) 2010-05-05 2011-11-10 Ratiopharm Gmbh Festes tapentadol in nicht-kristalliner form
EP3656765B1 (en) * 2010-07-23 2021-04-14 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
MX348831B (es) * 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
PT2680832T (pt) 2011-03-04 2019-10-28 Gruenenthal Gmbh Formulação farmacêutica aquosa de tapentadol para administração oral
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
LT2736497T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
USD730877S1 (en) 2013-09-06 2015-06-02 Plantronics, Inc. Communications headset
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
HRP20190231T1 (hr) 2015-03-27 2019-04-05 Grünenthal GmbH Stabilna formulacija za parenteralnu primjenu tapentadola
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
HRP20200029T1 (hr) 2016-04-19 2020-03-20 Ratiopharm Gmbh Kristalni tapentadol fosfat
JP7160799B2 (ja) 2016-09-23 2022-10-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与用安定製剤
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
WO2022098644A1 (en) 2020-11-03 2022-05-12 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
DE69717281T2 (de) * 1996-08-14 2003-09-04 G.D. Searle & Co., Chicago Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid
WO2002036542A1 (en) * 2000-10-31 2002-05-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
ES2314092T3 (es) * 2001-09-13 2009-03-16 Kissei Pharmaceutical Co., Ltd. Cristales de un derivado de hidroxinorefredina.
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
PT2240431T (pt) * 2007-12-07 2017-05-03 Gruenenthal Gmbh Modificações cristalinas de (1r,2r)-3-(3-dimetilamino-1- etil-2-metil-propil)fenol

Also Published As

Publication number Publication date
CA2572147A1 (en) 2006-01-05
US20200102261A1 (en) 2020-04-02
EP1799633A2 (en) 2007-06-27
AR116052A2 (es) 2021-03-25
BR122018014454B1 (pt) 2019-09-03
NO20160914A1 (no) 2007-01-24
PT1612203E (pt) 2007-08-20
EP1612203B1 (en) 2007-08-01
US20120302643A1 (en) 2012-11-29
NO341239B1 (no) 2017-09-25
NO20171103A1 (no) 2007-01-24
BR122018014454B8 (pt) 2021-07-27
EP1799633B1 (en) 2011-01-19
EP1612203A1 (en) 2006-01-04
JP2008504326A (ja) 2008-02-14
AU2005256512B2 (en) 2011-05-19
ES2291780T3 (es) 2008-03-01
MXPA06014741A (es) 2007-02-12
HRP20110050T1 (hr) 2011-02-28
WO2006000441A3 (en) 2006-05-04
US20090186947A1 (en) 2009-07-23
PL1799633T3 (pl) 2011-06-30
US20070213405A1 (en) 2007-09-13
SI1612203T1 (sl) 2007-12-31
JP4990764B2 (ja) 2012-08-01
ZA200700774B (en) 2008-09-25
NO20070162L (no) 2007-01-24
BRPI0512792A (pt) 2008-04-08
CN1997621A (zh) 2007-07-11
US20210261492A1 (en) 2021-08-26
CY1111530T1 (el) 2015-08-05
US7994364B2 (en) 2011-08-09
DE602005026031D1 (de) 2011-03-03
IL180373A (en) 2012-05-31
US20110294898A1 (en) 2011-12-01
PT1799633E (pt) 2011-03-07
NO338605B1 (no) 2016-09-12
RU2423345C2 (ru) 2011-07-10
CN1997621B (zh) 2011-06-15
HRP20110050T8 (en) 2011-03-31
RU2007103297A (ru) 2008-08-10
ATE496021T1 (de) 2011-02-15
KR101096501B1 (ko) 2011-12-20
DK1612203T3 (da) 2007-12-03
US20160122287A1 (en) 2016-05-05
DE602004007905D1 (de) 2007-09-13
US20200385334A1 (en) 2020-12-10
US20230174458A1 (en) 2023-06-08
CA2572147C (en) 2012-10-30
NO343922B1 (no) 2019-07-08
DK1799633T3 (da) 2011-03-28
WO2006000441A2 (en) 2006-01-05
US20190062263A1 (en) 2019-02-28
US20180230082A1 (en) 2018-08-16
ATE368639T1 (de) 2007-08-15
US20170166515A1 (en) 2017-06-15
US20100160447A1 (en) 2010-06-24
ES2359504T3 (es) 2011-05-24
PL1612203T3 (pl) 2007-12-31
CY1106929T1 (el) 2012-09-26
KR20070039929A (ko) 2007-04-13
US20140296346A1 (en) 2014-10-02
AU2005256512A1 (en) 2006-01-05
NZ551605A (en) 2010-01-29
AR049949A1 (es) 2006-09-20
IL180373A0 (en) 2007-06-03
SI1799633T1 (sl) 2011-05-31
US20140011886A1 (en) 2014-01-09
US20180029976A1 (en) 2018-02-01
ECSP17046065A (es) 2018-11-30
DE602004007905T2 (de) 2008-05-08

Similar Documents

Publication Publication Date Title
PE20060372A1 (es) Forma cristalina de clorhidrato de (-)-(1r, 2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
UY29406A1 (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen.
UY29405A1 (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la continen.
PE20071016A1 (es) Formas cristalinas de n-(benzo[b]tien-3-ilmetil)-sulfamida
ECSP066535A (es) Composiciones y formas de dosis para absorcion mejorada de gabapentina y pregabalina
GT200600346A (es) Nueva fórmula cristalina v de la agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen
AR109263A2 (es) Composición que comprende moxidectina
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
AR054777A1 (es) Modificaciones cristalinas de piraclostrobina
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
PE20081556A1 (es) Formas cristalinas de glyt1
AR060264A1 (es) Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion
AR038618A1 (es) Forma poliformica cristalina de clorhidratos de irinotecan
MX2007000117A (es) Una composicion de combinacion.
ES2422730T3 (es) Sales de tiotropio, procedimiento para su preparación, así como formulaciones de medicamentos que las contienen
PE20110119A1 (es) Asociacion entre ferroquina y artesunato para el tratamiento del paludismo
AR046402A1 (es) Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
PE20080134A1 (es) Sal nitrato de alisquireno
EP1853280A4 (en) COMPOSITIONS AND METHODS OF TREATING AND PREVENTING CARDIOMYOPATHY AND HERBAL DISEASE
AR026451A1 (es) Compuestos heterociclicos sililados
EP1570842A3 (en) Composition containing chondroitin sulphate

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration